Cosentyx vs Skyrizi
Side-by-side cost comparison based on Medicare Part D data
Cosentyx
Secukinumab
Manufactured by Novartis
Skyrizi
Risankizumab
Manufactured by AbbVie
Cosentyx costs 19% less per claim than Skyrizi ($3,616.00 vs $4,475.00). A generic version of Cosentyx is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Cosentyx | Skyrizi |
|---|---|---|
| Avg Cost Per Claim | $3,616.00 | $4,475.00 |
| Total Medicare Spending | $3.1B | $2.3B |
| Total Beneficiaries | 120,000 | 78,000 |
| Total Claims | 864,000 | 524,000 |
| Annual Cost/Patient | $26,033.00 | $30,064.00 |
| Year-over-Year Change | +8.9% | +42.8% |
| Generic Available | Yes | No |
| Patent Expiration | Jan 31, 2023 | Apr 23, 2035 |
| Manufacturer | Novartis | AbbVie |
| Condition | Autoimmune Diseases | Autoimmune Diseases |
| Generic Name | Secukinumab | Risankizumab |
Cosentyx vs Skyrizi: What the Data Shows
Cosentyx (Secukinumab) and Skyrizi (Risankizumab) are both used to treat autoimmune diseases. Based on Medicare Part D data, Cosentyx costs $3,616.00 per claim, which is 19% less than Skyrizi at $4,475.00 per claim.
Medicare spent $3.1B on Cosentyx and $2.3B on Skyrizi. In terms of patient reach, Cosentyx serves more beneficiaries (120,000 vs 78,000).
Year-over-year spending changed +8.9% for Cosentyx and +42.8% for Skyrizi. Skyrizi saw significant spending growth, suggesting increased utilization or price increases.
Cosentyx has a generic available, while Skyrizi remains brand-only until its patent expires Apr 23, 2035.
Frequently Asked Questions
Cosentyx is cheaper at $3,616.00 per claim, compared to $4,475.00 for Skyrizi. That makes Cosentyx about 19% less expensive per claim based on Medicare Part D data.
Yes, both Cosentyx and Skyrizi are used to treat autoimmune diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Cosentyx has a generic version (Secukinumab) available, which is typically much cheaper. Skyrizi is currently brand-only, with patent expiring Apr 23, 2035.
Medicare Part D spent $3.1B on Cosentyx covering 120,000 beneficiaries, and $2.3B on Skyrizi covering 78,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.